In Brief: Hoechst Marion Roussel's Anzemet
Executive Summary
Hoechst Marion Roussel's Anzemet: NDAs have been submitted for dolasetron mesylate for the prevention of nausea and vomiting in patients undergoing chemotherapy and surgery, company announces April 15. Anzemet is a 5-HT3 receptor antagonist in oral once-a-day and I.V. dosages...